Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:OCUL NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.05$4.69$3.97▼$9.18$282.73M1.54334,921 shs767,609 shsOCULOcular Therapeutix$8.94$8.90$6.23▼$16.44$1.96B0.92.39 million shs2.70 million shsRIGLRigel Pharmaceuticals$32.85$29.77$18.14▼$52.24$607.73M1.2306,346 shs241,516 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-3.57%-8.99%-19.80%-51.61%OCULOcular Therapeutix0.00%+8.36%-2.40%+3.59%+2.41%RIGLRigel Pharmaceuticals0.00%+9.76%+13.24%+23.73%+60.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.05$4.69$3.97▼$9.18$282.73M1.54334,921 shs767,609 shsOCULOcular Therapeutix$8.94$8.90$6.23▼$16.44$1.96B0.92.39 million shs2.70 million shsRIGLRigel Pharmaceuticals$32.85$29.77$18.14▼$52.24$607.73M1.2306,346 shs241,516 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-3.57%-8.99%-19.80%-51.61%OCULOcular Therapeutix0.00%+8.36%-2.40%+3.59%+2.41%RIGLRigel Pharmaceuticals0.00%+9.76%+13.24%+23.73%+60.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00245.68% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78165.97% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5065.91% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, BCYC, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BCYCBicycle Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/22/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/13/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$69.00 ➝ $81.005/7/2026RIGLRigel Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$71.00 ➝ $69.005/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RIGLRigel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M3.88N/AN/A$8.79 per share0.46OCULOcular Therapeutix$51.95M37.68N/AN/A$3.07 per share2.91RIGLRigel Pharmaceuticals$294.28M2.07$6.75 per share4.87$21.57 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.721.759.81N/A121.50%47.99%32.40%8/4/2026 (Estimated)Latest OCUL, BCYC, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66OCULOcular Therapeutix0.1214.8114.73RIGLRigel Pharmaceuticals0.042.622.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%OCULOcular Therapeutix59.21%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%OCULOcular Therapeutix3.10%RIGLRigel Pharmaceuticals10.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million63.88 millionOptionableOCULOcular Therapeutix230218.96 million212.17 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableOCUL, BCYC, and RIGL HeadlinesRecent News About These CompaniesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Hold" by AnalystsJune 12 at 2:25 AM | americanbankingnews.comInsider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel PharmaceuticalsJune 5, 2026 | benzinga.comThese 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocksJune 1, 2026 | seekingalpha.comInsider Selling: Rigel Pharmaceuticals (NASDAQ:RIGL) Director Sells 2,500 Shares of StockMay 29, 2026 | insidertrades.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 27, 2026 | prnewswire.comLilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches CompletionMay 22, 2026 | tipranks.comRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressMay 21, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) M&A Call - SlideshowMay 20, 2026 | seekingalpha.comRigel Shareholders Approve Equity Plans and Board SlateMay 20, 2026 | tipranks.comRigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?May 14, 2026 | finance.yahoo.comRigel to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceMay 14, 2026 | prnewswire.comThese Analysts Increase Their Forecasts On Arvinas After Q1 ResultsMay 13, 2026 | benzinga.comPfizer, Arvinas ink licensing deal with Rigel for breast cancer therapyMay 13, 2026 | seekingalpha.comRigel snaps up breast cancer drug Veppanu in up to $405m dealMay 13, 2026 | thepharmaletter.comTWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 10.76%May 13, 2026 | aaii.comARigel Pharmaceuticals, Inc. (RIGL) M&A Call TranscriptMay 12, 2026 | seekingalpha.comRigel Secures Global Rights to VEPPANU Breast Cancer TherapyMay 12, 2026 | tipranks.comRigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast CancerMay 12, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comRigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, BCYC, and RIGL Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.05 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$4.04 -0.01 (-0.22%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Ocular Therapeutix NASDAQ:OCUL$8.94 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$8.82 -0.12 (-1.35%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$32.85 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$32.52 -0.33 (-0.99%) As of 06/12/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
